New Haven antibiotics maker Melinta Therapeutics said it’s hired a former Shire vice president to lead its march toward commercialization.
Dr. Sue Cammarata will manage the development and registration strategy for Melinta’s portfolio of drugs.
The furthest along is delafloxacin, a treatment for drug-resistant skin infections that is in Phase 3 development in oral and intravenous formulations.
Melinta changed its name from Rib-X Pharmaceuticals in October. It’s raised more than $116 million in venture funding, according to Crunchbase.
